These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 18348679)

  • 41. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Nicholson SL; Brotchie JM
    Eur J Neurol; 2002 Nov; 9 Suppl 3():1-6. PubMed ID: 12464115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough.
    Lang AE; Obeso JA
    Lancet Neurol; 2004 May; 3(5):309-16. PubMed ID: 15099546
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Pharmacological treatments of Parkinson's disease].
    Nomoto M; Iwata S; Kaseda S
    Nihon Yakurigaku Zasshi; 2001 Feb; 117(2):111-22. PubMed ID: 11233302
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Parkinson's disease: new approaches to diagnosis and treatment.
    Yahr MD
    Acta Neurol Scand Suppl; 1993; 146():22-5. PubMed ID: 8333251
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disease-Modifying Drugs in Parkinson's Disease.
    Park A; Stacy M
    Drugs; 2015 Dec; 75(18):2065-71. PubMed ID: 26581672
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current and emerging therapeutic targets for Parkinson's disease.
    Pingale T; Gupta GL
    Metab Brain Dis; 2021 Jan; 36(1):13-27. PubMed ID: 33090348
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
    Dooley M; Markham A
    Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Unmet medical needs in Parkinson's disease.
    Koller WC; Tse W
    Neurology; 2004 Jan; 62(1 Suppl 1):S1-8. PubMed ID: 14718675
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel pharmacological strategies for motor complications in Parkinson's disease.
    Konitsiotis S
    Expert Opin Investig Drugs; 2005 Apr; 14(4):377-92. PubMed ID: 15882115
    [TBL] [Abstract][Full Text] [Related]  

  • 51. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
    Lipski J; Nistico R; Berretta N; Guatteo E; Bernardi G; Mercuri NB
    Prog Neurobiol; 2011 Sep; 94(4):389-407. PubMed ID: 21723913
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rationale for current therapies in Parkinson's disease.
    Romrell J; Fernandez HH; Okun MS
    Expert Opin Pharmacother; 2003 Oct; 4(10):1747-61. PubMed ID: 14521485
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine.
    Chase TN
    Neurology; 1998 May; 50(5 Suppl 5):S17-25. PubMed ID: 9591518
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of early Parkinson's disease.
    Grimes DA; Lang AE
    Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S39-44. PubMed ID: 10451759
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rethinking Parkinson's disease: could dopamine reduction therapy have clinical utility?
    Sackner-Bernstein J
    J Neurol; 2024 Aug; 271(8):5687-5695. PubMed ID: 38904783
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neural substrates and potential treatments for levodopa-induced dyskinesias in Parkinson's disease.
    Phillips JR; Eissa AM; Hewedi DH; Jahanshahi M; El-Gamal M; Keri S; Moustafa AA
    Rev Neurosci; 2016 Oct; 27(7):729-738. PubMed ID: 27362959
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design, Synthesis and In Vitro Evaluation of Levodopa Stearic Acid Hydrazide Conjugate for the Management of Parkinson's DiseaseNovel Conjugate for Parkinson's Disease.
    Chinraj V; Reddy RA; Selvaraj J; Sureshkumar R
    Drug Res (Stuttg); 2024 Feb; 74(2):60-66. PubMed ID: 38286420
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug therapy in the management of Parkinson's disease.
    Stevenson T
    Br J Nurs; 1997 Feb 13-26; 6(3):144-8, 150. PubMed ID: 9104119
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Levodopa-related wearing-off in Parkinson's disease: identification and management.
    Pahwa R; Lyons KE
    Curr Med Res Opin; 2009 Apr; 25(4):841-9. PubMed ID: 19228103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.